Denibulin

Denibulin (MN-029) is a novel small molecule Vascular Disrupting Agent (VDA) for treatment of solid tumor cancers. Denibulin binds reversibly to the colchicine-binding site on tubulin and inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor endothelial cells (EC), ultimately leading to a temporary reduction in tumor blood flow. Denibulin selectively disrupts newly-formed tumor blood vessels, shutting down tumor blood flow and causing central necrosis of solid tumors. A variety of rodent models, including nude mice and rats bearing human tumor xenografts, have been used to demonstrate the antitumor activity of Denibulin, both as monotherapy and in combination with chemotherapy or radiation.